Cystic Fibrosis Foundation to provide up to $11 million in additional funding to accelerate development of 4D-710 for cystic fibrosis, following program and clinical data review by its independent scientific advisors Funding supports second 4D-710 dosing ≥1 year post initial Phase 1 dose, advancement into Phase 2, and Phase 3 readinessEnrollment in the Phase 2 stage of the AEROW clinical trial is currently underway, with 2.5E14 vg selected as the anticipated pivotal and commercial dose EMERYVILLE, Calif., O ...